Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.

For many new chemical entities (NCE) of very low solubility oral bioavailability enhancement by micronisation is not sufficient, the next step taken was nanonisation. The production of drug nanocrystals by bottom up techniques (precipitation) is briefly described, main focus is given on particle diminution by high pressure homogenisation. Homogenisation can be performed in water (DissoCubes) or alternatively in non-aqueous media or water-reduced media (Nanopure). There is also a combination process of precipitation followed by a second high energy step, e.g. homogenisation (NANOEDGE). The result is a suspension of drug nanocrystals in a liquid, the so-called nanosuspension. Presented are the physical background of the diminution process, effects of production parameters (power density, number of homogenisation cycles) on crystal size, clinical batch production and scaling up of the production. As an important point the transfer of the liquid nanosuspensions to patient convenient oral dosage forms such as tablets and capsules is described.

[1]  Matthias Stieß,et al.  Mechanische Verfahrenstechnik 1 , 1992 .

[2]  P. Gassmann,et al.  Hydrosols : alternatives for the parenteral application of poorly water soluble drugs , 1994 .

[3]  R. Müller,et al.  Nanocrystals of Poorly Soluble Drugs for Oral Administration , 2003 .

[4]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[5]  N. Rasenack,et al.  Dissolution Rate Enhancement by in Situ Micronization of Poorly Water-Soluble Drugs , 2002, Pharmaceutical Research.

[6]  O. Kayser,et al.  for Poorly Soluble and Poorly Bioavailable Drugs , 2003 .

[7]  R. Müller,et al.  Intravenous itraconazole emulsions produced by SolEmuls technology. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  R. Müller,et al.  Formulation of intravenous carbamazepine emulsions by SolEmuls technology. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  C. Porter,et al.  LIPID-BASED FORMULATIONS FOR ORAL ADMINISTRATION: OPPORTUNITIES FOR BIOAVAILABILITY ENHANCEMENT AND LIPOPROTEIN TARGETING OF LIPOPHILIC DRUGS , 2001, Journal of receptor and signal transduction research.

[10]  C. Porter,et al.  In vitro assessment of oral lipid based formulations. , 2001, Advanced drug delivery reviews.

[11]  W. Higuchi,et al.  Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. , 1970, Journal of pharmaceutical sciences.

[12]  R. Müller,et al.  Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. , 2000, International journal of pharmaceutics.

[13]  B. Müller,et al.  Size controlled production of biodegradable microparticles with supercritical gases. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  W. Charman,et al.  Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. , 2000, Journal of pharmaceutical sciences.

[15]  Mitra Mosharraf,et al.  The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs , 1995 .

[16]  O. Kayser,et al.  DissoCubes‚ÄîA Novel Formulation for Poorly Soluble and Poorly Bioavailable Drugs , 2002 .